INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) is facing a Pomerantz LLP investigation into potential securities fraud tied to trial safety disclosures for nomlabofusp in Friedreich’s ataxia. Despite “positive” characterizations of data, the company reported anaphylaxis/severe allergic reactions in 7 participants (stock -33.66% to $3.38 on Sep 29, 2025) and later in 10 of 43 patients (stock -12.57% to $3.20 on Jun 29, 2026). The news underscores investor risk around clinical safety signals and potential disclosure practices.

Analysis

This is less a litigation headline than a valuation reset for a one-asset biotech with a fragile approval path. The market will likely keep discounting Larimar not on efficacy, but on whether the safety profile is compatible with a chronic, self-administered rare-disease regimen; in that framework, every incremental anaphylaxis case raises the expected cost of commercialization, slows physician adoption, and increases the odds of a labeling restriction, REMS-style burden, or outright regulatory delay.

The second-order winner is the incumbent standard-of-care franchise in Friedreich’s ataxia, most plausibly Biogen’s SKYCLOUS-style beneficiary set through BIIB, because a weaker alternative reduces switching pressure and makes payer formulary inertia easier to defend. The broader read-through is bearish for pre-revenue biotech multiples: investors will demand a much larger safety buffer for open-label data, especially when the asset already needs accelerated approval and has no diversified pipeline to absorb a setback. That can spill over into XBI/IBB sentiment if the market starts repricing class-wide approval odds for single-asset orphan names.

Near term, the catalyst path is binary: if FDA accepts the rolling BLA and does not impose a clinical hold, the stock can bounce mechanically on oversold positioning. Over 1-3 months, however, any additional safety disclosure, advisory committee scrutiny, or request for mitigation data would likely compress the equity further because the company’s bargaining power with regulators is weakening, not improving. Over 6-18 months, the key variable is whether the event rate stabilizes enough to be framed as manageable versus being interpreted as structurally incompatible with chronic use.

The contrarian point: the selloff may still be incomplete if the market is only pricing litigation and not the commercial math. Even a technically approvable drug can be economically impaired if severe hypersensitivity forces monitoring, training, and discontinuation rates that blunt uptake in a tiny market. The thesis is falsified if the FDA publicly signals comfort with the safety package, the label pathway remains clean, or management shows a credible mitigation strategy that stops new serious reactions without sacrificing dosing.

Key Decisions for Investors

• Short LRMR only on strength or post-rally, not into a flush; use a 1-3 month horizon and cover if the FDA accepts the BLA without additional safety requests. Risk/reward favors a tactical short, but borrow/liquidity may be the binding constraint.
• Prefer BIIB as a relative long versus LRMR for the next 3-6 months if you want to express the competitive read-through; the trade works only if Larimar’s safety issues continue to impair approval odds and adoption. Falsify if Larimar gets a clean regulatory path or if BIIB-specific launch data disappoints.
• Avoid naked options in LRMR unless borrow is unavailable; if you must express downside, use a small put spread around the next regulatory catalyst to cap theta bleed and gap risk. This is a binary biotech, so premium decay is the main enemy.
• Monitor FDA/BLA acceptance, any request for safety mitigation, and any new severe hypersensitivity disclosures as the real catalyst set. If no new safety signal appears over the next 4-8 weeks, a violent short squeeze is possible given the prior drawdowns.